Cargando…
Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017
BACKGROUND: The increased risk of adverse drug reactions due to age-related altered pharmacokinetics and pharmacodynamics is a challenge when prescribing medications to older people, and especially among older people with major neurocognitive disorder who are particularly sensitive to drug effects....
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245287/ https://www.ncbi.nlm.nih.gov/pubmed/35773643 http://dx.doi.org/10.1186/s12877-022-03240-y |
_version_ | 1784738713709838336 |
---|---|
author | Rangfast, Iris Sönnerstam, Eva Gustafsson, Maria |
author_facet | Rangfast, Iris Sönnerstam, Eva Gustafsson, Maria |
author_sort | Rangfast, Iris |
collection | PubMed |
description | BACKGROUND: The increased risk of adverse drug reactions due to age-related altered pharmacokinetics and pharmacodynamics is a challenge when prescribing medications to older people, and especially among older people with major neurocognitive disorder who are particularly sensitive to drug effects. The aim of this study was to investigate the use of potential inappropriate medications (PIMs) in 2012 and 2017 among old people with major neurocognitive disorder. A secondary aim was to investigate factors associated with PIM use. METHODS: This register-study was based on the Swedish registry for cognitive/dementia disorders and the Swedish prescribed drug register. Criteria from the National Board of Health and Welfare were used to identify PIMs between 1 July–31 December 2012 and 1 July-–31 December 2017 among people ≥ 65 years. Drug use was defined as one or more filled prescriptions during each timeframe. RESULTS: The total use of PIMs declined significantly between 2012 (28.7%) and 2017 (21.7%). All PIMs and PIM groups declined between these years, except for antipsychotic drugs, which increased from 11.6% to 12.3%. The results from the multiple regression model found that PIM use was associated with younger age (OR: 0.97 CI: 0.96–0.97), a lower Mini Mental State Examination score (OR: 0.99 CI: 0.99–1.00), the use of multi-dispensed drugs (OR: 2.05 CI: 1.93–2.18), and compared to Alzheimer’s disease, with the subtypes dementia with Lewy bodies and Parkinson’s disease dementia (OR: 1.57 CI: 1.40–1.75), frontotemporal dementia (OR: 1.29 CI: 1.08–1.54) and vascular dementia (OR: 1.10 CI: 1.03–1.16). CONCLUSIONS: Overall, the use of PIMs decreased between the years 2012 and 2017. The increase of antipsychotic drugs and the association between PIM use and multi-dispensed drugs warrant concern. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-03240-y. |
format | Online Article Text |
id | pubmed-9245287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92452872022-07-01 Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 Rangfast, Iris Sönnerstam, Eva Gustafsson, Maria BMC Geriatr Research BACKGROUND: The increased risk of adverse drug reactions due to age-related altered pharmacokinetics and pharmacodynamics is a challenge when prescribing medications to older people, and especially among older people with major neurocognitive disorder who are particularly sensitive to drug effects. The aim of this study was to investigate the use of potential inappropriate medications (PIMs) in 2012 and 2017 among old people with major neurocognitive disorder. A secondary aim was to investigate factors associated with PIM use. METHODS: This register-study was based on the Swedish registry for cognitive/dementia disorders and the Swedish prescribed drug register. Criteria from the National Board of Health and Welfare were used to identify PIMs between 1 July–31 December 2012 and 1 July-–31 December 2017 among people ≥ 65 years. Drug use was defined as one or more filled prescriptions during each timeframe. RESULTS: The total use of PIMs declined significantly between 2012 (28.7%) and 2017 (21.7%). All PIMs and PIM groups declined between these years, except for antipsychotic drugs, which increased from 11.6% to 12.3%. The results from the multiple regression model found that PIM use was associated with younger age (OR: 0.97 CI: 0.96–0.97), a lower Mini Mental State Examination score (OR: 0.99 CI: 0.99–1.00), the use of multi-dispensed drugs (OR: 2.05 CI: 1.93–2.18), and compared to Alzheimer’s disease, with the subtypes dementia with Lewy bodies and Parkinson’s disease dementia (OR: 1.57 CI: 1.40–1.75), frontotemporal dementia (OR: 1.29 CI: 1.08–1.54) and vascular dementia (OR: 1.10 CI: 1.03–1.16). CONCLUSIONS: Overall, the use of PIMs decreased between the years 2012 and 2017. The increase of antipsychotic drugs and the association between PIM use and multi-dispensed drugs warrant concern. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12877-022-03240-y. BioMed Central 2022-06-30 /pmc/articles/PMC9245287/ /pubmed/35773643 http://dx.doi.org/10.1186/s12877-022-03240-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rangfast, Iris Sönnerstam, Eva Gustafsson, Maria Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title | Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title_full | Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title_fullStr | Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title_full_unstemmed | Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title_short | Prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
title_sort | prevalence of potentially inappropriate medications among old people with major neurocognitive disorder in 2012 and 2017 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245287/ https://www.ncbi.nlm.nih.gov/pubmed/35773643 http://dx.doi.org/10.1186/s12877-022-03240-y |
work_keys_str_mv | AT rangfastiris prevalenceofpotentiallyinappropriatemedicationsamongoldpeoplewithmajorneurocognitivedisorderin2012and2017 AT sonnerstameva prevalenceofpotentiallyinappropriatemedicationsamongoldpeoplewithmajorneurocognitivedisorderin2012and2017 AT gustafssonmaria prevalenceofpotentiallyinappropriatemedicationsamongoldpeoplewithmajorneurocognitivedisorderin2012and2017 |